The finding highlights the potential of CXCR2 antagonists as a therapy for COPD, since CXCR2 inhibitor may inhibit the chemotaxis of blood monocytes and neutrophils into the lung. This evidence concerns the gene CXCR2 and chronic obstructive pulmonary disease.